相关实验视频
Updated: Jun 11, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
早期非小细胞肺癌的阿帕蒂尼布单疗法:一个病例报告
Jiafang Xu1, Qingjie Hu2, Siqi Yin2
1Reproductive Medicine Center, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
Journal of cardiothoracic surgery
|October 1, 2024
概括
阿帕提尼布单一疗法对未能接受标准治疗的患者的早期非小细胞肺癌 (NSCLC) 具有前景. 这种早期的NSCLC治疗在64个月内耐受性良好且有效,这表明进一步研究的潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 第一个阶段的非小细胞肺癌 (NSCLC) 是一个重大的临床挑战,其转移率高,治疗后复发.
- 目前早期NSCLC的治疗选择,包括手术,射频废除和免疫治疗,不适合所有患者.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
1.7K